The first antibiotic, salvarsan, was deployed in 1910. In just over 100 years antibiotics have
drastically changed modern medicine and extended the average human lifespan by 23 …

Antibacterial resistance is one of the greatest threats to human health. The development of
new therapeutics against bacterial pathogens has slowed drastically since the approvals of …

Natural products and their structural analogues have historically made a major contribution
to pharmacotherapy, especially for cancer and infectious diseases. Nevertheless, natural …

We are experiencing an antimicrobial resistance (AMR) crisis, brought on by the drying up of
the antibiotic discovery pipeline and the resulting unchecked spread of resistant pathogens …

Actinobacteria constitute a highly diverse bacterial phylum with an unrivalled metabolic
versatility. They produce most of the clinically used antibiotics and a plethora of other natural …

Biodiversity is adversely affected by the growing levels of synthetic chemicals released into
the environment due to agricultural activities. This has been the driving force for embracing …

Discovery of antibiotics acting against Gram-negative species is uniquely challenging due to
their restrictive penetration barrier. BamA, which inserts proteins into the outer membrane, is …

Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a promising
source of new antimicrobials in the face of rising antibiotic resistance. Here, we report a …

Covering: 2006 to 2017 Actinomycetes have been, for decades, one of the most important
sources for the discovery of new antibiotics with an important number of drugs and analogs …

Understanding of the capacity of the natural world to produce secondary metabolites is
important to a broad range of fields, including drug discovery, ecology, biosynthesis, and …